AstraZeneca’s respiratory franchise is expected to see a significant boost with the assumption of Almirall’s pipeline of novel respiratory assets.
via Marketing - United States - Latest News http://ift.tt/1ADrrSw
via Marketing - United States - Latest News http://ift.tt/1ADrrSw
Keine Kommentare:
Kommentar veröffentlichen